Patent Application for Antisense Oligonucleotide Targeting TDP-43 mRNA

The United States Patent and Trademark Office (USPTO) has published patent application US20260085310A1, filed by NIPPON SHINYAKU CO., LTD. The application details an antisense oligonucleotide designed to target TDP-43 mRNA or pre-mRNA, consisting of 15 to 22 nucleotides complementary to specific regions of SEQ ID NO: 1. This relates to potential treatments for conditions involving TDP-43.

This publication represents a new patent application and does not impose immediate compliance obligations on regulated entities. However, companies in the pharmaceutical and biotechnology sectors, particularly those involved in oligonucleotide therapeutics or neurodegenerative disease research, should be aware of this filing as it pertains to intellectual property in this area. No compliance actions or deadlines are associated with this patent application publication itself.